Agenus is seeking U.S. approval of balstilimab, its investigational immunotherapy for the treatment of recurrent or metastatic cervical cancer, which has limited effective treatment options and disproportionately affects younger people. The company has begun a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA). This means it will submit individual sections of the application as soon as each one is completed, rather than waiting to submit the entire…
You must be logged in to read/download the full post.
The post Agenus Begins Rolling Submission of Balstilimab to FDA for Advanced Cervical Cancer appeared first on BioNewsFeeds.